GHRP-6

GHRP-6 is a synthetic hexapeptide and the compound that opened this field. Derived in the 1980s from work on met-enkephalin fragments that unexpectedly prompted growth hormone release, it demonstrated that a small synthetic peptide could do something no known hormone was responsible for — which implied an unidentified receptor and an unidentified natural signal.

That implication was correct. The receptor was cloned in 1996 and named the growth hormone secretagogue receptor after the compounds that had found it; the natural hormone activating it, ghrelin, was identified in 1999. GHRP-6 is therefore best understood not as an imitation of ghrelin but as the molecule whose behaviour proved ghrelin had to exist.

Its most distinctive property in practice is appetite. Of the peptides at this receptor, GHRP-6 produces the strongest hunger response — a direct consequence of engaging the receptor for a hormone whose principal job is signalling that the stomach is empty. For research into feeding behaviour that is the point; for research into growth hormone it is the main reason to choose something else.

• It found the receptor: Its activity was the evidence that a previously unknown receptor and hormone existed, and the search it prompted produced both. That makes it a landmark compound in endocrinology rather than merely an early one.

• Appetite signalling: The strong hunger response makes it the tool of choice when feeding behaviour is the object of study rather than an unwanted side of it, and it appears throughout the ghrelin literature for exactly that reason.

• The unselective baseline: It engages the receptor broadly and moves several hormones at once. That makes it the reference point against which selectivity in later compounds is defined and measured.

• Tissue protection models: Ghrelin receptors occur outside the pituitary, including in the heart and gut, and a separate strand of work examines this peptide in those tissues — where the question is not growth hormone at all.

Ghrelin is produced mainly in the stomach lining and rises before meals; it is one of the body's clearest "empty" signals. Its receptor is found in the pituitary, where it contributes to growth hormone release, and in the hypothalamus, where it feeds into the circuits governing appetite. One hormone, one receptor, two quite different jobs depending on where the receptor happens to sit.

GHRP-6 engages that receptor wherever it occurs, so both jobs respond. Pituitary cells release growth hormone; hypothalamic circuits register a hunger signal. This is not an off-target effect in the usual sense — it is the same receptor doing what it does in a different location, which is a distinction worth keeping clear when reading results.

The growth hormone response itself runs through a different internal pathway from the GHRH one, which is why compounds from the two families produce more together than either does alone. GHRP-6 is the oldest member of its family and the least discriminating, and everything that came after it in this class was an attempt to keep the pituitary response while losing the rest.

The historical and mechanistic record is strong. Its discovery, its role in identifying the ghrelin system, its receptor binding and its effects on growth hormone and appetite are all documented in peer-reviewed literature spanning nearly forty years, and reproduced independently.

There is no approved use and no completed clinical programme, and it is supplied for laboratory research only. Studies measure feeding behaviour and hormone concentrations under controlled conditions. That is its role: it is the compound whose activity revealed the ghrelin system, and it remains the standard tool for the appetite side of it.

GHRP-2 is the more potent sibling with a somewhat narrower response, and the two are almost always discussed as a pair. Ipamorelin is the selective third generation, and the clearest way to understand what it was designed to fix is to read what this compound does.

CJC-1295 engages the separate GHRH receptor on the same cells, which is why cross-family comparisons are routine here. The two receptor systems converge on one output through genuinely independent routes.